Every 8-K that GLOBUS MEDICAL INC (GMED) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GMED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GMED filings page.
Globus Medical reported second quarter 2026 results with worldwide net sales of $789.6 million, up 5.9% year over year, or 5.6% on a constant currency basis. U.S. net sales grew 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis, supported by growth in US Spine and International Spine.
GAAP net income for the quarter was $151.6 million, and GAAP diluted EPS was $1.10, down 26.2% from the prior-year period primarily because the prior year included a $110.5 million bargain purchase gain related to the Nevro acquisition. On a non-GAAP basis, diluted EPS rose 55.8% to $1.34, and Adjusted EBITDA reached $279,839 (in thousands), or 35.4% of net sales, alongside 200 basis points of adjusted gross margin expansion.
For the first six months of 2026, total net sales grew 15.3% year over year. Net cash provided by operating activities was $412,105 (in thousands), supporting free cash flow of $339,322 (in thousands) and total cash, cash equivalents and marketable securities of $840,500 (in thousands). The company reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised its non-GAAP fully diluted EPS outlook to $4.95–$5.05 from $4.70–$4.80.
Globus Medical, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2021 Equity Incentive Plan to add 1,000,000 additional shares, bringing the total shares authorized for issuance under the plan to 12,000,000 Class A common shares.
The amendment also raised the limit on shares that may be issued as incentive stock options to 12,000,000. Stockholders elected two Class II directors to serve until the 2029 annual meeting, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved 2025 executive compensation on an advisory basis.
Globus Medical delivered a strong start to 2026, with first quarter worldwide net sales of $759.9 million, up 27.0% year over year, or 25.5% on a constant currency basis. Base business net sales excluding Nevro were $677.2 million, up 13.2%.
GAAP net income rose to $124.3 million, an increase of 64.7%, while GAAP diluted EPS climbed to $0.90. Non-GAAP diluted EPS was $1.12, up 64.7%. Net sales from the Nevro acquisition contributed $82.7 million in the quarter.
The company reaffirmed its 2026 revenue outlook of $3.18 billion to $3.22 billion and raised its full-year non-GAAP diluted EPS guidance to $4.70–$4.80 from $4.40–$4.50, reflecting margin expansion and expected benefits from operating leverage and acquisition synergies.
Globus Medical, Inc. reported that Board member John A. DeFord, Ph.D. resigned from the Board of Directors effective immediately on March 23, 2026. The company stated that his decision was not due to any disagreement with the company.
In a related press release, Globus Medical noted that Dr. DeFord will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026, and highlighted his contributions, including work during the merger with NuVasive and service on the Nominating and Governance Committee.
Globus Medical reported a strong finish to 2025 with robust growth in sales, profit and cash flow. Fourth quarter 2025 worldwide net sales were $826.4 million, up 25.7% year over year, while GAAP net income rose to $140.6 million and GAAP diluted EPS reached $1.03, with non-GAAP diluted EPS at $1.28.
For full year 2025, worldwide net sales were $2,938.9 million, up 16.7%, and GAAP net income grew to $537.9 million, driving GAAP diluted EPS of $3.92 and non-GAAP diluted EPS of $3.98. Base business net sales excluding Nevro were $2,645.3 million, up 5.0%, highlighting meaningful contribution from the Nevro acquisition.
Adjusted EBITDA for 2025 was $919.6 million, or 31.3% of net sales, and free cash flow reached $588.8 million. Management reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised non-GAAP diluted EPS guidance to $4.40–$4.50, signaling confidence in continued growth and margin expansion.
Globus Medical, Inc. reported preliminary unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025. At the same time, the company issued preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026, giving investors an early view of expected performance for the coming year. These updates were shared through a press release dated January 7, 2026, which is furnished as an exhibit to this report.
Globus Medical (GMED) filed an 8-K stating it issued a press release reporting sales and operating results for the three- and nine-month periods ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information under Item 2.02 and the related exhibit are “furnished” and not “filed” for purposes of Section 18 of the Exchange Act.